Recent Insider Transactions Derivative • Jun 07
CEO & Director notifies of intention to sell stock Marc Stapley intends to sell 138k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of June. If the sale is conducted around the recent share price of US$48.69, it would amount to US$6.7m. For the year to December 2021, Marc's total compensation was 9% salary and 91% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Marc's direct individual holding has increased from 135.55k shares to 143.90k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jun 02
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S Veracyte, Inc. announced the U.S. commercial launch of the Prosigna Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient’s ROR score and estimates the 10-year probability of distant recurrence, providing prognostic insight into how a patient’s cancer may behave over time. These insights also help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy or may safely achieve optimal outcomes with endocrine therapy alone, enabling clinicians to make personalized care plans for their patients. The Prosigna test will be available to order starting June 8, 2026. In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%. It is critically important to accurately determine a patient’s risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient’s life. The Prosigna test is the only breast cancer test that factors a patient's biological, clinical, and pathological information into a single comprehensive analysis. The test uniquely combines intrinsic subtypes and proliferation score with clinical factors to determine a patient's ROR score and predict the 10-year probability of distant recurrence. This long-term risk assessment provides clinically meaningful insight beyond initial diagnosis, particularly in early-stage breast cancer where recurrence can occur many years later. For decades, clinical risk factors have been a key factor in treatment decisions. Currently, for many patients with high-risk breast cancer who are premenopausal and node positive, standard of care is still chemotherapy and endocrine therapy. New data from the OPTIMA trial shows that nodal involvement and other clinical risk factors do not automatically equate to high risk of recurrence -- for the first time, more than two-thirds of node-positive patients who previously might have received chemotherapy can now safely avoid it based on the Prosigna test results. The Prosigna test was developed from the PAM50 genomic classifier, a foundation for understanding breast cancer biology, which classifies a patient’s individual tumor into one of the four intrinsic subtypes. The Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence. The Prosigna test is the only test proven to be predictive for chemotherapy benefit decisions in a phase III prospective trial for premenopausal and postmenopausal women with high-risk breast cancer, including those with extensive nodal involvement (up to 9 positive nodes). Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window. The PAM50 signature was designed to unlock the clinical utility of modern biological insights into the nature of breast cancer. Through the Prosigna test, these biological insights are now directly informing treatment decisions for patients. The OPTIMA results reinforces the need to ground critical decisions upon tumor biology because understanding risk of recurrence and chemotherapy benefit as distinct principles produces safer and more personalized care. Patients diagnosed with early-stage breast cancer deserve access to the most advanced testing available, with the most up to date evidence, so they can make informed treatment decisions with their medical oncology team. Prosigna's ability to accurately predict risk of recurrence means patients may have the option to avoid chemotherapy and its significant side effects or confidently pursue more aggressive treatment when it will truly benefit them. Veracyte is committed to making the Prosigna test accessible to all eligible breast cancer patients. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. 
